Alpha Technology's financing

Recently, Shenzhen Alpha Molecular Technology Co., Ltd. (hereinafter referred to as "Alpha Technology") completed the first round of financing of tens of millions of yuan, which will be used for the company's research and development activities to obtain preclinical drug molecules in the next year and a half. This round of financing was supported by New Value and listed company Poinsettia Pharmaceutical (300723. SZ) and Shenzhen High-tech Investment Co-participated. This is the layout of the computer-aided drug search track after full investigation, recognition of the excellent R&D capabilities of the founding team of Alpha Technology and prediction of the future explosive development potential of the company's pipeline.

Introduction to Alpha Tech

Alpha Technology is a start-up biopharmaceutical enterprise established in July 2020 for AI-assisted new drug research and development, incubated by Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, with the responsibility of solving the pain points of weak key technologies in domestic new drug research and development, and using biocomputing, artificial intelligence and original biotechnology for new drug innovation. The core team of Alpha Technology is composed of PhDs from the R&D departments of large Swiss pharmaceutical companies and professors from Swiss universities, led by Academician Horst Vogel and Dr. Yuan Shuguang, experts in the field. The company's team members have rich experience in promoting the research and development of "first-in-class" clinical new drugs, and have also invented a series of world-first biotechnologies, including: the world's first optical biochip to test G protein-coupled receptor protein (GPCR, the most important drug development target, nearly 7% of marketed drugs are developed for GPCR), the world's first biochip to test cell electrophysiology, the world's first biochip to track single-molecule cells, etc. Recently, the team has made a major breakthrough in cryo-EM technology of raw cell membranes, creating a new chapter in the design of drugs based on precise target structures. At present, the company has established a complete new drug development pipeline combining theoretical calculation and experiment. The company has a number of international scientists in the field of GPCR and a series of original core technologies of GPCR. The company will focus on the research and development of new drugs for GPCR and its related signaling pathways for major human diseases.

Introduction of New Value:

Shenzhen XinValue Capital Management Co., Ltd. is a private equity fund management company registered and filed by Asset Management Association of China Securities Regulatory Commission (record number: P1003636) focusing on investment in the fields of artificial intelligence, biomedical, advanced manufacturing and TMT. The company's core shareholders manage more than 200 billion yuan of corporate assets, located in the Shenzhen-Hong Kong Modern Service Industry Cooperation Zone - Shenzhen Qianhai, and approved by Shenzhen Qianhai Administration and Shenzhen Market Supervision Administration, is a private equity investment fund management institution with fund management, investment management and investment consulting as its main business.

The company has a management team with a global vision and background that is familiar with the global economy, capital market, financial market, and the latest scientific and technological development trends, in-depth and professional industrial dynamics and industry research, so as to make accurate investment value judgments for investors, so as to create value for investors and society.